

Alexa B Kimball

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2109916/publications.pdf>

Version: 2024-02-01

278
papers

18,609
citations

16411

64
h-index

14156

128
g-index

283
all docs

283
docs citations

283
times ranked

11381
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). <i>Lancet</i> , The, 2008, 371, 1665-1674. | 6.3 | 1,572 |
| 2 | Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 106-115. | 0.6 | 796 |
| 3 | Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 405-417. | 0.6 | 673 |
| 4 | Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. <i>New England Journal of Medicine</i> , 2015, 373, 1318-1328. | 13.9 | 656 |
| 5 | IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. <i>Journal of Experimental Medicine</i> , 2006, 203, 2577-2587. | 4.2 | 610 |
| 6 | Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. <i>New England Journal of Medicine</i> , 2016, 375, 422-434. | 13.9 | 530 |
| 7 | Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE) <i>Tj ETQq1 1 0.784314 rgBT /Overl</i> | 6.3 | 428 |
| 8 | The Psychosocial Burden of Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2005, 6, 383-392. | 3.3 | 421 |
| 9 | National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 1031-1042. | 0.6 | 383 |
| 10 | Adalimumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa. <i>Annals of Internal Medicine</i> , 2012, 157, 846. | 2.0 | 349 |
| 11 | Development and validation of the International Hidradenitis Suppurativa Severity Score System (I) <i>Tj ETQq1 1 0.784314 rgBT /Overl</i> <i>Dermatology</i> , 2017, 177, 1401-1409. | 1.4 | 301 |
| 12 | Hidradenitis suppurativa. <i>Nature Reviews Disease Primers</i> , 2020, 6, 18. | 18.1 | 286 |
| 13 | Association Between Biologic Therapies for Chronic Plaque Psoriasis and Cardiovascular Events. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 864-71. | 3.8 | 259 |
| 14 | Quantifying the harmful effect of psoriasis on health-related quality of life. <i>Journal of the American Academy of Dermatology</i> , 2002, 47, 512-518. | 0.6 | 237 |
| 15 | Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: A chart-verified case-control analysis. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 1144-1150. | 0.6 | 235 |
| 16 | The US dermatology workforce: A specialty remains in shortage. <i>Journal of the American Academy of Dermatology</i> , 2008, 59, 741-745. | 0.6 | 222 |
| 17 | North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 76-90. | 0.6 | 218 |
| 18 | Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 333-337. | 1.3 | 217 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Text-Message Reminders to Improve Sunscreen Use. Archives of Dermatology, 2009, 145, 1230-6. | 1.7 | 213 |
| 20 | Safety and Efficacy of ABT-874, a Fully Human Interleukin 12/23 Monoclonal Antibody, in the Treatment of Moderate to Severe Chronic Plaque Psoriasis. Archives of Dermatology, 2008, 144, 200. | 1.7 | 207 |
| 21 | North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations. Journal of the American Academy of Dermatology, 2019, 81, 91-101. | 0.6 | 206 |
| 22 | Determining the relative importance of patient motivations for nonadherence to topical corticosteroid therapy in psoriasis. Journal of the American Academy of Dermatology, 2006, 55, 607-613. | 0.6 | 189 |
| 23 | The Response of Skin Disease to Stress. Archives of Dermatology, 2003, 139, 897-900. | 1.7 | 187 |
| 24 | Psoriasis: is the impairment to a patient's life cumulative?. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 989-1004. | 1.3 | 180 |
| 25 | Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial. Journal of the American Academy of Dermatology, 2010, 63, 457-465. | 0.6 | 180 |
| 26 | Hidradenitis suppurativa: Epidemiology and scope of the problem. Journal of the American Academy of Dermatology, 2015, 73, S4-S7. | 0.6 | 173 |
| 27 | Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization – systematic review and recommendations from the HS ALLIANCE working group. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 19-31. | 1.3 | 168 |
| 28 | Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 1535-1545. | 1.3 | 166 |
| 29 | Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): Why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. Journal of the American Academy of Dermatology, 2012, 66, 369-375. | 0.6 | 158 |
| 30 | Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment. British Journal of Dermatology, 2014, 171, 1434-1442. | 1.4 | 156 |
| 31 | Cardiovascular Disease and Risk Factors among Psoriasis Patients in Two US Healthcare Databases, 2001-2002. Dermatology, 2008, 217, 27-37. | 0.9 | 155 |
| 32 | Risks of developing psychiatric disorders in pediatric patients with psoriasis. Journal of the American Academy of Dermatology, 2012, 67, 651-657.e2. | 0.6 | 149 |
| 33 | Topical Chemotherapy in Cutaneous T-cell Lymphoma. JAMA Dermatology, 2013, 149, 25. | 2.0 | 147 |
| 34 | HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 989-994. | 1.3 | 137 |
| 35 | The dermatology workforce shortage. Journal of the American Academy of Dermatology, 2004, 50, 50-54. | 0.6 | 136 |
| 36 | Magnetic resonance imaging detection of occult skin and subcutaneous abnormalities in juvenile dermatomyositis: Implications for diagnosis and therapy. Arthritis and Rheumatism, 2000, 43, 1866-1873. | 6.7 | 132 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Pregnancy Outcomes After Exposure to Certolizumab Pegol. <i>Arthritis and Rheumatology</i> , 2018, 70, 1399-1407. | 2.9 | 129 |
| 38 | The Impact of Administrative Burden on Academic Physicians: Results of a Hospital-Wide Physician Survey. <i>Academic Medicine</i> , 2017, 92, 237-243. | 0.8 | 126 |
| 39 | Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): Results from analyses of infections and malignancy from pooled phase II and III clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2012, 66, 742-751. | 0.6 | 124 |
| 40 | Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. <i>British Journal of Dermatology</i> , 2012, 166, 861-872. | 1.4 | 121 |
| 41 | Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 117-122. | 0.6 | 120 |
| 42 | Comparison of the epidemiology of acne vulgaris among Caucasian, Asian, Continental Indian and African American women. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 1054-1060. | 1.3 | 119 |
| 43 | Systemic associations of hidradenitis suppurativa. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, S27-S35. | 0.6 | 115 |
| 44 | Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis. <i>Drug Safety</i> , 2016, 39, 755-762. | 1.4 | 112 |
| 45 | Topical vitamins, minerals and botanical ingredients as modulators of environmental and chronological skin damage. <i>British Journal of Dermatology</i> , 2003, 149, 681-691. | 1.4 | 109 |
| 46 | Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR). <i>British Journal of Dermatology</i> , 2014, 171, 137-147. | 1.4 | 104 |
| 47 | The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study. <i>British Journal of Dermatology</i> , 2011, 165, 1066-1073. | 1.4 | 103 |
| 48 | Economic burden of comorbidities in patients with psoriasis is substantial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 157-163. | 1.3 | 100 |
| 49 | The burden of autoimmune disease: A comparison of prevalence ratios in patients with psoriatic arthritis and psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2009, 61, 405-410. | 0.6 | 99 |
| 50 | Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2012, 67, 76-85. | 0.6 | 99 |
| 51 | Co-occurrence and comorbidities in patients with immune-mediated inflammatory disorders: an exploration using US healthcare claims data, 2001-2002. <i>Current Medical Research and Opinion</i> , 2006, 22, 989-1000. | 0.9 | 95 |
| 52 | Impact of adalimumab treatment on patient-reported outcomes: Results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis. <i>Journal of Dermatological Treatment</i> , 2007, 18, 341-350. | 1.1 | 91 |
| 53 | What causes hidradenitis suppurativa 15 years after. <i>Experimental Dermatology</i> , 2020, 29, 1154-1170. | 1.4 | 90 |
| 54 | Acne Vulgaris in Women: Prevalence Across the Life Span. <i>Journal of Women's Health</i> , 2012, 21, 223-230. | 1.5 | 86 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Who else is providing care in dermatology practices? Trends in the use of nonphysician clinicians. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 211-216. | 0.6 | 84 |
| 56 | Psoriasis Epidemiology: The Interplay of Genes and the Environment. <i>Journal of Investigative Dermatology</i> , 2013, 133, 287-289. | 0.3 | 84 |
| 57 | Pediatric Psoriasis Comorbidity Screening Guidelines. <i>JAMA Dermatology</i> , 2017, 153, 698. | 2.0 | 84 |
| 58 | Rethinking the Psoriasis Area and Severity Index: the impact of area should be increased. <i>British Journal of Dermatology</i> , 2004, 151, 381-387. | 1.4 | 83 |
| 59 | Psychometric properties of the Itch Numeric Rating Scale in patients with moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2016, 175, 157-162. | 1.4 | 81 |
| 60 | Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR). <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 70-80. | 0.6 | 78 |
| 61 | Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 1092-1101. | 0.6 | 77 |
| 62 | Update on biologic safety for patients with psoriasis during pregnancy. <i>International Journal of Women's Dermatology</i> , 2017, 3, 21-25. | 1.1 | 76 |
| 63 | Impact of Endometriosis on Life-Course Potential: A Narrative Review. <i>International Journal of General Medicine</i> , 2021, Volume 14, 9-25. | 0.8 | 75 |
| 64 | Cutaneous effects of BRAF inhibitor therapy: a case series. <i>Annals of Oncology</i> , 2013, 24, 530-537. | 0.6 | 73 |
| 65 | Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and) https://doi.org/10.1093/ibd/ibab107 | 1.0 | 73 |
| 66 | Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 936-945. | 0.6 | 71 |
| 67 | Increased diagnosis of thin superficial spreading melanomas: A 20-year study. <i>Journal of the American Academy of Dermatology</i> , 2012, 67, 387-394. | 0.6 | 68 |
| 68 | Prevalence and Risk of Inflammatory Bowel Disease in Patients with Hidradenitis Suppurativa. <i>Journal of Investigative Dermatology</i> , 2017, 137, 1060-1064. | 0.3 | 68 |
| 69 | The Impact of Psoriasis on Pregnancy Outcomes. <i>Journal of Investigative Dermatology</i> , 2012, 132, 85-91. | 0.3 | 66 |
| 70 | Striae gravidarum. <i>Clinics in Dermatology</i> , 2006, 24, 97-100. | 0.8 | 65 |
| 71 | A Single-Blinded, Randomized, Controlled Clinical Trial Evaluating the Effect of Face Washing on Acne Vulgaris. <i>Pediatric Dermatology</i> , 2006, 23, 421-427. | 0.5 | 63 |
| 72 | Clinical Goals and Barriers to Effective Psoriasis Care. <i>Dermatology and Therapy</i> , 2019, 9, 5-18. | 1.4 | 63 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 115-122. | 0.6 | 62 |
| 74 | Clinical and Immunologic Assessment of Patients With Psoriasis in a Randomized, Double-blind, Placebo-Controlled Trial Using Recombinant Human Interleukin 10. <i>Archives of Dermatology</i> , 2002, 138, 1341-6. | 1.7 | 61 |
| 75 | Meta-analysis comparing efficacy of benzoyl peroxide, clindamycin, benzoyl peroxide with salicylic acid, and combination benzoyl peroxide/clindamycin in acne. <i>Journal of the American Academy of Dermatology</i> , 2010, 63, 52-62. | 0.6 | 60 |
| 76 | Few Medicaid and uninsured patients are accessing dermatologists. <i>Journal of the American Academy of Dermatology</i> , 2006, 55, 1084-1088. | 0.6 | 59 |
| 77 | Accumulating Evidence for the Association and Shared Pathogenic Mechanisms Between Psoriasis and Cardiovascular-related Comorbidities. <i>American Journal of Medicine</i> , 2014, 127, 1148-1153. | 0.6 | 59 |
| 78 | Using the Physician Global Assessment in a Clinical Setting to Measure and Track Patient Outcomes. <i>JAMA Dermatology</i> , 2015, 151, 375. | 2.0 | 59 |
| 79 | Cutaneous manifestations of thyroid disease. <i>Clinics in Dermatology</i> , 2008, 26, 283-287. | 0.8 | 57 |
| 80 | Latitude and psoriasis prevalence. <i>Journal of the American Academy of Dermatology</i> , 2011, 65, 870-873. | 0.6 | 57 |
| 81 | Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials. <i>British Journal of Dermatology</i> , 2018, 179, 615-622. | 1.4 | 57 |
| 82 | Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized <sc>VOYAGE</sc> 1 and <sc>VOYAGE</sc> 2 studies. <i>British Journal of Dermatology</i> , 2019, 180, 1039-1049. | 1.4 | 57 |
| 83 | Patient-Reported Outcomes and Health-Care Resource Utilization in Patients with Psoriasis Treated with Etanercept: Continuous versus Interrupted Treatment. <i>Value in Health</i> , 2008, 11, 400-407. | 0.1 | 56 |
| 84 | Reduction in the appearance of facial hyperpigmentation after use of moisturizers with a combination of topical niacinamide and N-acetyl glucosamine: results of a randomized, double-blind, vehicle-controlled trial. <i>British Journal of Dermatology</i> , 2010, 162, 435-441. | 1.4 | 55 |
| 85 | Antiandrogen therapy with spironolactone for the treatment of hidradenitis suppurativa. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 114-119. | 0.6 | 54 |
| 86 | Itching is a significant problem and a mediator between disease severity and quality of life for patients with psoriasis: results from a randomized controlled trial. <i>British Journal of Dermatology</i> , 2014, 171, 1215-1219. | 1.4 | 53 |
| 87 | Efficacy and Safety of Adalimumab among Patients with Moderate to Severe Psoriasis with Co-Morbidities. <i>American Journal of Clinical Dermatology</i> , 2011, 12, 51-62. | 3.3 | 52 |
| 88 | Meta-analysis comparing efficacy of antibiotics versus oral contraceptives in acne vulgaris. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 450-459. | 0.6 | 52 |
| 89 | Psoriasis and psoriatic arthritis: separate or one and the same?. <i>British Journal of Dermatology</i> , 2007, 157, 850-860. | 1.4 | 51 |
| 90 | The Comorbidity Burden of Hidradenitis Suppurativa in the United States: A Claims Data Analysis. <i>Dermatology and Therapy</i> , 2018, 8, 557-569. | 1.4 | 51 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Age-induced and photoinduced changes in gene expression profiles in facial skin of Caucasian females across 6 decades of age. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 29-39.e7. | 0.6 | 50 |
| 92 | Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 333-339. | 1.3 | 50 |
| 93 | Longer-term impact of cardiology e-consults. <i>American Heart Journal</i> , 2016, 173, 86-93. | 1.2 | 49 |
| 94 | Incidence rates of malignancies and hospitalized infectious events in patients with psoriasis with or without treatment and a general population in the U.S.A.: 2005-09. <i>British Journal of Dermatology</i> , 2014, 170, 366-373. | 1.4 | 48 |
| 95 | Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory. <i>British Journal of Dermatology</i> , 2014, 170, 705-715. | 1.4 | 48 |
| 96 | Quality of Life and Treatment Satisfaction among Patients with Psoriasis and Psoriatic Arthritis and Patients with Psoriasis Only. <i>American Journal of Clinical Dermatology</i> , 2008, 9, 111-117. | 3.3 | 45 |
| 97 | Accessibility to air travel correlates strongly with increasing melanoma incidence*. <i>Melanoma Research</i> , 2006, 16, 77-81. | 0.6 | 44 |
| 98 | Patient navigation based on predictive modeling decreases no-show rates in cancer care. <i>Cancer</i> , 2015, 121, 1662-1670. | 2.0 | 43 |
| 99 | Disease burden and cost of hidradenitis suppurativa: a retrospective examination of US administrative claims data. <i>BMJ Open</i> , 2019, 9, e030579. | 0.8 | 43 |
| 100 | US Dermatology Residents' Satisfaction With Training and Mentoring. <i>Archives of Dermatology</i> , 2008, 144, 896-900. | 1.7 | 42 |
| 101 | New antifungal therapies for the treatment of onychomycosis. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 727-734. | 1.9 | 42 |
| 102 | Self-Reported Acne Severity, Treatment, and Belief Patterns across Multiple Racial and Ethnic Groups in Adolescent Students. <i>Pediatric Dermatology</i> , 2010, 27, 446-452. | 0.5 | 40 |
| 103 | Cohort study of malignancies and hospitalized infectious events in treated and untreated patients with psoriasis and a general population in the United States. <i>British Journal of Dermatology</i> , 2015, 173, 1183-1190. | 1.4 | 40 |
| 104 | Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 1156-1161. | 0.6 | 39 |
| 105 | Tofacitinib shows benefit in conjunction with other therapies in recalcitrant hidradenitis suppurativa patients. <i>JAAD Case Reports</i> , 2020, 6, 99-102. | 0.4 | 39 |
| 106 | Cumulative Life Course Impairment: Evidence for Psoriasis. <i>Current Problems in Dermatology</i> , 2013, 44, 82-90. | 0.8 | 38 |
| 107 | The validity of the diagnostic code for hidradenitis suppurativa in an electronic database. <i>British Journal of Dermatology</i> , 2014, 171, 338-342. | 1.4 | 37 |
| 108 | Gender and Parenting Significantly Affect Work Hours of Recent Dermatology Program Graduates. <i>Archives of Dermatology</i> , 2004, 140, 191-6. | 1.7 | 36 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Management of Hidradenitis Suppurativa Wounds with an Internal Vacuum-Assisted Closure Device. <i>Plastic and Reconstructive Surgery</i> , 2014, 133, 370e-377e. | 0.7 | 36 |
| 110 | Targeted Reminder Phone Calls to Patients at High Risk of No-Show for Primary Care Appointment: A Randomized Trial. <i>Journal of General Internal Medicine</i> , 2016, 31, 1460-1466. | 1.3 | 36 |
| 111 | Brodalumab and suicidal ideation in the context of a recent economic crisis in the United States. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 190-192. | 0.6 | 36 |
| 112 | Dermatology: A unique case of specialty workforce economics. <i>Journal of the American Academy of Dermatology</i> , 2003, 48, 265-270. | 0.6 | 35 |
| 113 | Striae and Pelvic Relaxation: Two Disorders of Connective Tissue with a Strong Association. <i>Journal of Investigative Dermatology</i> , 2006, 126, 1745-1748. | 0.3 | 35 |
| 114 | Briakinumab. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 1107-1113. | 1.4 | 35 |
| 115 | Early development and qualitative evidence of content validity for the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure of psoriasis symptom severity. <i>Journal of Dermatological Treatment</i> , 2013, 24, 255-260. | 1.1 | 35 |
| 116 | Fate of manuscripts declined by the <i>Journal of the American Academy of Dermatology</i> . <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 632-635. | 0.6 | 34 |
| 117 | Psoriasis prevalence among the 2009 AAD National Melanoma/Skin Cancer Screening Program participants. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 680-685. | 1.3 | 34 |
| 118 | Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials. <i>British Journal of Dermatology</i> , 2019, 181, 967-975. | 1.4 | 34 |
| 119 | Pregnancy outcomes in psoriasis: Why do we know so little?. <i>Journal of the American Academy of Dermatology</i> , 2009, 61, e5-e8. | 0.6 | 33 |
| 120 | Development and initial psychometric evaluation of patient-reported outcome questionnaires to evaluate the symptoms and impact of hidradenitis suppurativa. <i>Journal of Dermatological Treatment</i> , 2018, 29, 152-164. | 1.1 | 33 |
| 121 | TNF- α inhibitors in the treatment of hidradenitis suppurativa. <i>Therapeutic Advances in Chronic Disease</i> , 2019, 10, 204062231985164. | 1.1 | 33 |
| 122 | Seasonal variation of acne and psoriasis: A 3-year study using the Physician Global Assessment severity scale. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 523-525. | 0.6 | 32 |
| 123 | Controlled nail trephination for subungual hematoma. <i>American Journal of Emergency Medicine</i> , 2006, 24, 875-877. | 0.7 | 31 |
| 124 | OBSERVE-5 interim analysis: An observational postmarketing safety registry of etanercept for the treatment of psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2013, 68, 756-764. | 0.6 | 31 |
| 125 | Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years. <i>Journal of Drugs in Dermatology</i> , 2018, 17, 826-832. | 0.4 | 31 |
| 126 | Efficacy and safety of ABT-874, a monoclonal anti-interleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60-week open-label extension phases of a randomized phase II trial. <i>Journal of the American Academy of Dermatology</i> , 2011, 64, 263-274. | 0.6 | 30 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | Current guidelines for psoriasis treatment: a work in progress. <i>Cutis</i> , 2018, 101, 10-12. | 0.4 | 30 |
| 128 | Aging-Associated Changes in the Adult Human Skin Microbiome and the Host Factors that Affect Skin Microbiome Composition. <i>Journal of Investigative Dermatology</i> , 2022, 142, 1934-1946.e21. | 0.3 | 29 |
| 129 | Telehealth Use by Age and Race at a Single Academic Medical Center During the COVID-19 Pandemic: Retrospective Cohort Study. <i>Journal of Medical Internet Research</i> , 2021, 23, e23905. | 2.1 | 28 |
| 130 | Health Disparities Among Different Ethnic and Racial Middle and High School Students in Sun Exposure Beliefs and Knowledge. <i>Journal of Adolescent Health</i> , 2010, 47, 106-109. | 1.2 | 26 |
| 131 | Psoriasis and Cardiovascular Disease. <i>Medical Clinics of North America</i> , 2015, 99, 1227-1242. | 1.1 | 26 |
| 132 | Eruptive Xanthomas Associated With Olanzapine Use. <i>Archives of Dermatology</i> , 2003, 139, 1045-8. | 1.7 | 25 |
| 133 | Counterpoint: Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, 818-819. | 0.6 | 25 |
| 134 | Beyond the blot: cutting edge tools for genomics, proteomics and metabolomics analyses and previous successes. <i>British Journal of Dermatology</i> , 2012, 166, 1-8. | 1.4 | 24 |
| 135 | Self-Reported Help-Seeking Behaviors and Treatment Choices of Adolescents Regarding Acne. <i>Pediatric Dermatology</i> , 2013, 30, 36-41. | 0.5 | 24 |
| 136 | Diffuse morbilliform eruption after consumption of ginkgo biloba supplement. <i>Journal of the American Academy of Dermatology</i> , 2002, 46, 145-146. | 0.6 | 23 |
| 137 | Skin carotenoid levels in adult patients with psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 945-949. | 1.3 | 22 |
| 138 | Psoriasis patients' willingness to accept side-effect risks for improved treatment efficacy. <i>Journal of Dermatological Treatment</i> , 2015, 26, 507-513. | 1.1 | 22 |
| 139 | Systemic causes of hair loss. <i>Annals of Medicine</i> , 2016, 48, 393-402. | 1.5 | 22 |
| 140 | Secukinumab improves scalp pain, itching, scaling and quality of life in patients with moderate-to-severe scalp psoriasis. <i>Journal of Dermatological Treatment</i> , 2017, 28, 716-721. | 1.1 | 22 |
| 141 | Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 294-301.e6. | 0.6 | 22 |
| 142 | Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab. <i>British Journal of Dermatology</i> , 2020, 182, 180-189. | 1.4 | 22 |
| 143 | Comorbidities of hidradenitis suppurativa. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2017, 36, 55-57. | 1.6 | 22 |
| 144 | Acne and oral contraceptives: Update on women's health screening guidelines. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 781-786. | 0.6 | 21 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 145 | Meta-analysis of randomized controlled trials using 5% benzoyl peroxide and clindamycin versus 2.5% benzoyl peroxide and clindamycin topical treatments in acne. <i>Journal of the American Academy of Dermatology</i> , 2011, 65, e117-e119. | 0.6 | 21 |
| 146 | Long-term Impact of Ixekizumab on Psoriasis Itch Severity: Results from a Phase III Clinical Trial and Long-term Extension. <i>Acta Dermato-Venereologica</i> , 2018, 98, 98-102. | 0.6 | 21 |
| 147 | Adalimumab alleviates skin pain in patients with moderate-to-severe hidradenitis suppurativa: Secondary efficacy results from the PIONEER I and PIONEER II randomized controlled trials. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 1141-1143. | 0.6 | 21 |
| 148 | Biologic Treatment for Hidradenitis Suppurativa. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 625-638. | 3.3 | 21 |
| 149 | Pregnancy Outcomes in Women With Moderate-to-Severe Psoriasis From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). <i>JAMA Dermatology</i> , 2021, 157, 301. | 2.0 | 21 |
| 150 | Adverse Reactions to Biologics in Psoriasis. <i>Current Problems in Dermatology</i> , 2018, 53, 1-14. | 0.8 | 20 |
| 151 | Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies. <i>British Journal of Dermatology</i> , 2020, 182, 1359-1368. | 1.4 | 20 |
| 152 | Psoriasis and herpes simplex virus are highly stigmatizing compared with other common dermatologic conditions: A survey-based study. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 525-526. | 0.6 | 19 |
| 153 | Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized <sc>VOYAGE</sc> 1 trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1515-1522. | 1.3 | 19 |
| 154 | Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1098-1106. | 1.3 | 19 |
| 155 | Efficacy and Tolerability of a Cosmetically Acceptable Coal Tar Solution in the Treatment of Moderate Plaque Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2010, 11, 1. | 3.3 | 18 |
| 156 | A novel approach to administration of peptides in women: Systemic absorption of a GnRH agonist via transvaginal ring delivery system. <i>Journal of Controlled Release</i> , 2016, 233, 19-28. | 4.8 | 18 |
| 157 | Metabolic dysfunction in human skin: Restoration of mitochondrial integrity and metabolic output by nicotinamide (niacinamide) in primary dermal fibroblasts from older aged donors. <i>Aging Cell</i> , 2020, 19, e13248. | 3.0 | 18 |
| 158 | Risk of COVID-19 in dermatologic patients receiving long-term immunomodulatory therapy. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1215-1218. | 0.6 | 18 |
| 159 | <sc>IL-17A</sc> is a pertinent therapeutic target for moderate-to-severe hidradenitis suppurativa: Combined results from a pre-clinical and phase <sc>II</sc> proof-of-concept study. <i>Experimental Dermatology</i> , 2022, 31, 1522-1532. | 1.4 | 18 |
| 160 | Reporting of ethical review of clinical research submitted to the <i>Journal of the American Academy of Dermatology</i> . <i>Journal of the American Academy of Dermatology</i> , 2007, 56, 279-284. | 0.6 | 17 |
| 161 | Chronic pain management in dermatology. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 563-573. | 0.6 | 17 |
| 162 | Achieving Hidradenitis Suppurativa Response Score is Associated with Significant Improvement in Clinical and Patient-reported Outcomes: Post Hoc Analysis of Pooled Data From PIONEER I and II. <i>Acta Dermato-Venereologica</i> , 2018, 98, 932-937. | 0.6 | 17 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 163 | Clobetasol propionate foam in the treatment of psoriasis. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 1735-1740. | 0.9 | 16 |
| 164 | Itch intensity in moderate-to-severe plaque psoriasis versus atopic dermatitis: A meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 1198-1200.e1. | 0.6 | 16 |
| 165 | Genetic basis for skin youthfulness. <i>Clinics in Dermatology</i> , 2019, 37, 312-319. | 0.8 | 16 |
| 166 | Baseline Characteristics from UNITE: An Observational, International, Multicentre Registry to Evaluate Hidradenitis Suppurativa (Acne Inversa) in Clinical Practice. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 579-590. | 3.3 | 16 |
| 167 | Weight loss in obese patients with psoriasis can be successfully achieved during a course of phototherapy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 1582-1584. | 1.3 | 15 |
| 168 | The relative impact of psoriasis and obesity on socioeconomic and medical outcomes in psoriasis patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 216-221. | 1.3 | 15 |
| 169 | Unmet clinical needs and burden of disease in hidradenitis suppurativa: real-world experience from EU5 and US. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1597-1605. | 1.3 | 15 |
| 170 | A measure of chronic quality of life predicts socioeconomic and medical outcomes in psoriasis patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 249-254. | 1.3 | 14 |
| 171 | Getting under the Skin: Report from the International Psoriasis Council Workshop on the Role of Stress in Psoriasis. <i>Frontiers in Psychology</i> , 2016, 7, 87. | 1.1 | 14 |
| 172 | Predictions, Surprises, and the Future of the Dermatology Workforce. <i>JAMA Dermatology</i> , 2018, 154, 1253. | 2.0 | 14 |
| 173 | Reliability of the hidradenitis suppurativa clinical response in the assessment of patients with hidradenitis suppurativa. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 2254-2256. | 1.3 | 14 |
| 174 | Workforce Characteristics of Mohs Surgery Fellows. <i>Dermatologic Surgery</i> , 2004, 30, 136-138. | 0.4 | 13 |
| 175 | Long-term safety of biologics in dermatology. <i>Dermatologic Therapy</i> , 2009, 22, 2-21. | 0.8 | 13 |
| 176 | Examining the prior authorization process, patient outcomes, and the impact of a pharmacy intervention: A single-center review. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 1308-1318. | 0.6 | 13 |
| 177 | Publication trends in hidradenitis suppurativa from 2008 to 2018. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1885-1889. | 1.3 | 13 |
| 178 | Overview and update on biologic therapy for moderate-to-severe hidradenitis suppurativa. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2018, 37, 182-189. | 1.6 | 13 |
| 179 | Targeting IL-23: Insights into the pathogenesis and the treatment of psoriasis. <i>Indian Journal of Dermatology</i> , 2010, 55, 171. | 0.1 | 13 |
| 180 | Cytarabine-induced acute generalized exanthematous pustulosis. <i>Journal of the American Academy of Dermatology</i> , 2002, 47, 633-635. | 0.6 | 12 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 181 | Rising educational debt levels in recent dermatology trainees and effects on career choices. <i>Journal of the American Academy of Dermatology</i> , 2006, 54, 329-331. | 0.6 | 12 |
| 182 | Skin sun-acne tutorial evaluation among middle- and high-school students in central New Jersey. <i>Journal of the American Academy of Dermatology</i> , 2007, 56, 407-412. | 0.6 | 12 |
| 183 | A Single-Blinded, Randomized Pilot Study to Evaluate the Effect of Exercise-Induced Sweat on Truncal Acne. <i>Pediatric Dermatology</i> , 2008, 25, 126-128. | 0.5 | 12 |
| 184 | Socioeconomic disability in psoriasis. <i>British Journal of Dermatology</i> , 2009, 161, 1410-1412. | 1.4 | 12 |
| 185 | Chronic pain management in dermatology. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 575-582. | 0.6 | 12 |
| 186 | Managing the dose escalation of biologics in an era of cost containment: the need for a rational strategy. <i>International Journal of Women's Dermatology</i> , 2016, 2, 151-153. | 1.1 | 12 |
| 187 | An assessment of the relative impact of hidradenitis suppurativa, psoriasis, and obesity on quality of life. <i>International Journal of Women's Dermatology</i> , 2018, 4, 198-202. | 1.1 | 12 |
| 188 | Online communications among hidradenitis suppurativa patients reflect community needs. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1760-1762. | 0.6 | 12 |
| 189 | Skin Differences, Needs, and Disorders across Global Populations. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2008, 13, 2-5. | 0.8 | 11 |
| 190 | Teaching empathy to undergraduate medical students using a temporary tattoo simulating psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2012, 67, 93-99. | 0.6 | 11 |
| 191 | Understanding the cost of dermatologic care: A survey study of dermatology providers, residents, and patients. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 609-617. | 0.6 | 11 |
| 192 | Baseline patient-reported outcomes from <sc>UNITE</sc>: an observational, international, multicentre registry to evaluate hidradenitis suppurativa in clinical practice. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1302-1308. | 1.3 | 11 |
| 193 | Biologic therapies for the treatment of hidradenitis suppurativa. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 621-633. | 1.4 | 11 |
| 194 | Psoriasis severity: commonly used clinical thresholds may not adequately convey patient impact. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 417-421. | 1.3 | 11 |
| 195 | Clobetasol propionate emollient formulation foam in the treatment of corticosteroid-responsive dermatoses. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 2001-2007. | 0.9 | 10 |
| 196 | The temporal association between cutaneous T-cell lymphoma and psoriasis: implications for common biologic processes. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, e31-e32. | 1.3 | 10 |
| 197 | Correlation of psoriasis activity with socioeconomic status: cross-sectional analysis of patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). <i>British Journal of Dermatology</i> , 2018, 179, 984-986. | 1.4 | 10 |
| 198 | Plastic Surgical Management of Hidradenitis Suppurativa. <i>Plastic and Reconstructive Surgery</i> , 2021, 147, 479-491. | 0.7 | 10 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 199 | An assessment of the cost-utility of therapy for psoriasis. <i>Therapeutics and Clinical Risk Management</i> , 2006, 2, 325-328. | 0.9 | 10 |
| 200 | The dermatology life quality index (DLQI) provides qualitatively different information from the pasi. <i>Journal of the American Academy of Dermatology</i> , 2004, 50, P156. | 0.6 | 9 |
| 201 | How Low Should You Go: Novel Device for Nail Trephination. <i>Dermatologic Surgery</i> , 2006, 32, 828-833. | 0.4 | 9 |
| 202 | Survey Research in Dermatology: Guidelines for Success. <i>Dermatologic Clinics</i> , 2009, 27, 121-131. | 1.0 | 9 |
| 203 | Hidradenitis Suppurativa. <i>JAMA Dermatology</i> , 2014, 150, 1263. | 2.0 | 9 |
| 204 | Delivering value in dermatology: Insights from skin cancer detection in routine clinical visits. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 310-313. | 0.6 | 9 |
| 205 | Investigating race and gender in age at onset of hidradenitis suppurativa. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e139-e141. | 1.3 | 9 |
| 206 | Melanoma in Hong Kong between 1983 and 2002: a decreasing trend in incidence observed in a complex socio-political and economic setting. <i>Melanoma Research</i> , 2010, 20, 427-430. | 0.6 | 9 |
| 207 | Survey on Clinician Perceptions and Practices Regarding Goals of Care Conversations. <i>Journal of Palliative Medicine</i> , 2016, 19, 1215-1217. | 0.6 | 8 |
| 208 | Should We Leave the Skin Biopsies to the Dermatologists?. <i>JAMA Dermatology</i> , 2016, 152, 371. | 2.0 | 8 |
| 209 | Methotrexate shows benefit in a subset of patients with severe hidradenitis suppurativa. <i>International Journal of Women's Dermatology</i> , 2020, 6, 159-163. | 1.1 | 8 |
| 210 | Treatment Outcomes Associated With Dupilumab Use in Patients With Atopic Dermatitis. <i>JAMA Dermatology</i> , 2022, 158, 142. | 2.0 | 8 |
| 211 | Practice patterns among osteopathic dermatologists in the United States. <i>Journal of the American Academy of Dermatology</i> , 2007, 56, 524-525. | 0.6 | 7 |
| 212 | Letter: Medical Versus Surgical Dermatology: How Much Training do Residents Receive?. <i>Dermatologic Surgery</i> , 2006, 32, 597-597. | 0.4 | 6 |
| 213 | Leadership Workforce in Academic Dermatology. <i>Archives of Dermatology</i> , 2007, 143, 948-9. | 1.7 | 6 |
| 214 | Future perspectives/quo vadis psoriasis treatment? Immunology, pharmacogenomics, and epidemiology. <i>Clinics in Dermatology</i> , 2008, 26, 554-561. | 0.8 | 6 |
| 215 | Re. major life-changing decisions and cumulative life course impairment. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 246-246. | 1.3 | 6 |
| 216 | Specializing in Accountability. <i>Academic Medicine</i> , 2013, 88, 1900-1903. | 0.8 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 217 | A safety review of biologic therapies for the management of hidradenitis suppurativa and unmet needs. Expert Opinion on Drug Safety, 2021, 20, 1147-1161. | 1.0 | 6 |
| 218 | The spectrum of nephrocutaneous diseases and associations. Journal of the American Academy of Dermatology, 2016, 74, 231-244. | 0.6 | 5 |
| 219 | The spectrum of nephrocutaneous diseases and associations. Journal of the American Academy of Dermatology, 2016, 74, 247-270. | 0.6 | 5 |
| 220 | Performing research in pregnancy: Challenges and perspectives. Clinics in Dermatology, 2016, 34, 410-415. | 0.8 | 5 |
| 221 | AB0912â€¦Two-year efficacy and safety of guselkumab for treatment of moderate-to-severe psoriasis: phase 3 voyage 1 trial. , 2018, , . | | 5 |
| 222 | High placebo rates in clinical trials: Is the problem scoring systems or drug efficacy?. Journal of the American Academy of Dermatology, 2020, 83, e431. | 0.6 | 5 |
| 223 | Hidradenitis suppurativa disease course during pregnancy and postpartum: a retrospective survey study. British Journal of Dermatology, 2021, 185, 1072-1074. | 1.4 | 5 |
| 224 | Impact of childhood atopic dermatitis on life decisions for caregivers and families. Journal of the European Academy of Dermatology and Venereology, 2022, 36, . | 1.3 | 5 |
| 225 | Advances in the treatment of acne. Journal of reproductive medicine, The, 2008, 53, 742-52. | 0.2 | 5 |
| 226 | OBSERVE-5, an Observational Post-Marketing Safety Surveillance Registry of Etanercept for the Treatment of Psoriasis: A Model for Studying New Psoriasis Therapies. Psoriasis Forum, 2010, 16a, 3-7. | 0.1 | 4 |
| 227 | Acne Knowledge of Hispanic Parents of Teenagers with Mild to Moderate Acne. Pediatric Dermatology, 2016, 33, e292-e293. | 0.5 | 4 |
| 228 | A visit guide for hidradenitis suppurativaâ€”Managing a complex disease in a busy clinic. Journal of the American Academy of Dermatology, 2021, 84, e155-e160. | 0.6 | 4 |
| 229 | Transcriptomic analysis of human skin wound healing and rejuvenation following ablative fractional laser treatment. PLoS ONE, 2021, 16, e0260095. | 1.1 | 4 |
| 230 | The Yin and Yang of Skin Microbiota in â€œSwimmer Acneâ€. Experimental Dermatology, 2022, , . | 1.4 | 4 |
| 231 | Advances in biologic and small molecule therapies for hidradenitis suppurativa. Expert Opinion on Pharmacotherapy, 2022, 23, 959-978. | 0.9 | 4 |
| 232 | A Cost-effectiveness Comparison of Liquor Carbonis Distillate Solution and Calcipotriol Cream in the Treatment of Moderate Chronic Plaque Psoriasis. Archives of Dermatology, 2010, 146, 919-22. | 1.7 | 3 |
| 233 | Dermatology urgent care: Enlisting help from primary care in triage decisions. Journal of the American Academy of Dermatology, 2014, 71, 838-839. | 0.6 | 3 |
| 234 | Real-time location systems, normative messaging and modifying clinician behavior: a pilot study. Health Systems, 2014, 3, 165-172. | 0.9 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 235 | Effects of <sc>TNF</sc>α antagonist in patients with metabolic syndrome and psoriasis. Journal of the European Academy of Dermatology and Venereology, 2016, 30, e152-e154. | 1.3 | 3 |
| 236 | Understanding patient engagement in psoriasis treatment. British Journal of Dermatology, 2018, 178, 988-989. | 1.4 | 3 |
| 237 | Burnout Among All Groups of Physiciansâ€™ Mitigation Strategies for Dermatologists. JAMA Dermatology, 2020, 156, 1049. | 2.0 | 3 |
| 238 | Psoriasis: Knowledge, attitudes and perceptions among primary care providers. Journal of the American Academy of Dermatology, 2021, 84, 1421-1423. | 0.6 | 3 |
| 239 | Hidradenitis suppurativa scoring systems: can we choose just one?. Cutis, 2017, 99, 156-157. | 0.4 | 3 |
| 240 | Rethinking eligibility creep. Journal of the American Academy of Dermatology, 2008, 59, 165-167. | 0.6 | 2 |
| 241 | Targeting the IL-12/IL-23 cytokine family in the treatment of psoriatic disease. Expert Review of Dermatology, 2008, 3, 453-463. | 0.3 | 2 |
| 242 | Ketoconazole 2% foam for treatment of seborrheic dermatitis. Expert Review of Dermatology, 2008, 3, 15-21. | 0.3 | 2 |
| 243 | Psoriasis and cardiovascular disease: another contribution in the hierarchy of evidence. British Journal of Dermatology, 2012, 167, 1198-1199. | 1.4 | 2 |
| 244 | Validation of a Screening Instrument for Nephrogenic Systemic Fibrosis. Arthritis Care and Research, 2013, 65, 637-642. | 1.5 | 2 |
| 245 | An evaluation of educational debt levels in dermatology residents and effects on career choices. Journal of the American Academy of Dermatology, 2014, 70, 1141-1142. | 0.6 | 2 |
| 246 | Expanding Scope of Dermatologic Mid-Level Practitioners Includes Prescription of Complex Medication. JAMA Dermatology, 2015, 151, 106. | 2.0 | 2 |
| 247 | Observations from our evaluation of bodyweight changes after initiation of a biologic therapy in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). Journal of the European Academy of Dermatology and Venereology, 2017, 31, e544-e547. | 1.3 | 2 |
| 248 | Psoriasis and latitude: Analytic approaches and future data needs. Journal of the American Academy of Dermatology, 2017, 77, e59. | 0.6 | 2 |
| 249 | Assessment of treatment-seeking behaviour in patients with psoriasis. British Journal of Dermatology, 2018, 179, 989-990. | 1.4 | 2 |
| 250 | Use of biologics in pregnancy: limitations stemming from clinical trials and registry experience. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e276-e277. | 1.3 | 2 |
| 251 | Hidradenitis Suppurativa Epidemiology. , 2022, , 10-17. | | 2 |
| 252 | Hidradenitis suppurativa for the dermatologic hospitalist. Cutis, 2019, 104, 276-280. | 0.4 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 253 | Treatment Satisfaction and Health-related Quality of Life among Individuals with Psoriasis: National Psoriasis Foundation Survey Findings. <i>Psoriasis Forum</i> , 2008, 14a, 27-34. | 0.1 | 1 |
| 254 | Patient preferences for dermatology visits. <i>Journal of the American Academy of Dermatology</i> , 2009, 61, 1083-1084. | 0.6 | 1 |
| 255 | Correspondence: Assessing dermatology board examination competence using questions distribution: a 12-year Brazilian experience. <i>International Journal of Dermatology</i> , 2010, 49, 1080-1082. | 0.5 | 1 |
| 256 | Association of systemic psoriasis therapies and incidence of myocardial infarction: reply from authors. <i>British Journal of Dermatology</i> , 2012, 166, 233-233. | 1.4 | 1 |
| 257 | A new era in skin care: the omics revolution. <i>British Journal of Dermatology</i> , 2012, 166, iii-iv. | 1.4 | 1 |
| 258 | Dermatologic workforce on the Texas border: using burden on primary care as an outcome measure. <i>International Journal of Dermatology</i> , 2013, 52, 506-507. | 0.5 | 1 |
| 259 | Prevalence of Skin Disorders in Patients Seeking Health Care. <i>Mayo Clinic Proceedings</i> , 2013, 88, 776. | 1.4 | 1 |
| 260 | Treatment of Moderate to Severe Hidradenitis Suppurativa. <i>Annals of Internal Medicine</i> , 2013, 159, 72. | 2.0 | 1 |
| 261 | Unerwünschte Wirkungen von Biologika bei Psoriasis. <i>Karger Kompass Dermatologie</i> , 2017, 5, 195-199. | 0.0 | 1 |
| 262 | Pharmacoeconomics of Systemic and Biologic Therapy in Dermatology. , 2018, , 83-91. | | 1 |
| 263 | Etanercept reduces pruritus in patients with moderate to severe psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2004, 50, P155. | 0.6 | 0 |
| 264 | Innovative care, medical research, and the ethics of informed consent. <i>Journal of the American Academy of Dermatology</i> , 2007, 56, 330-332. | 0.6 | 0 |
| 265 | Skin and Anti-Aging Research Update: Proceedings from the 2007 World Congress of Dermatology. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2008, 13, 1. | 0.8 | 0 |
| 266 | Impact of Film ("My Skin's on Fire: Living With Psoriasis") on Medical Student Education in Dermatology. <i>Journal of the Dermatology Nurses' Association</i> , 2009, 1, 190-194. | 0.1 | 0 |
| 267 | Skin carotenoid levels are not associated with risk of nonmelanoma skin cancer: Response to ðœSupplement use and the risk of cutaneous squamous cell carcinomaðœ. <i>Journal of the American Academy of Dermatology</i> , 2012, 67, 1071-1072. | 0.6 | 0 |
| 268 | Teachable Action for Leaders Committed to Improving Physician Work Life: Continuing Education. <i>Mayo Clinic Proceedings</i> , 2015, 90, 1455-1456. | 1.4 | 0 |
| 269 | The Utility of Laser Thermometry in Grading Plaque Psoriasis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2015, 1, 15-17. | 0.3 | 0 |
| 270 | A Closer Inspection of the Number Needed to BiopsyðœReply. <i>JAMA Dermatology</i> , 2016, 152, 953. | 2.0 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 271 | 28 CHARACTERISTICS AND OUTCOMES OF PROSPECTIVELY REPORTED PREGNANCIES EXPOSED TO CERTOLIZUMAB PEGOL FROM A SAFETY DATABASE. <i>Gastroenterology</i> , 2018, 154, S9-S10. | 0.6 | 0 |
| 272 | Reply to: "Lack of a US Food and Drug Administration indication should not limit access to appropriate treatment". <i>Journal of the American Academy of Dermatology</i> , 2019, 81, e19-e20. | 0.6 | 0 |
| 273 | Quantifying Itch: Measurement on the Way to Management. , 2021, 107, 167-168. | | 0 |
| 274 | Response to Letter to the Editor entitled: Rethinking biologic and pregnancy research: The importance of assessing postpartum immunosuppression of the infant. <i>International Journal of Women's Dermatology</i> , 2021, 7, 510-511. | 1.1 | 0 |
| 275 | Clinical Evaluation. , 2022, , 62-68. | | 0 |
| 276 | Refining how we measure as we test: new insights using adalimumab in patients with hidradenitis suppurativa. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 2342-2342. | 1.3 | 0 |
| 277 | Effects of swimming on facial sebum in adolescents. <i>Pediatric Dermatology</i> , 2021, , . | 0.5 | 0 |
| 278 | Dermatologic inflammatory conditions require high loading and maintenance doses of biologic therapy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, . | 1.3 | 0 |